
HCYTD
Healthcare · Biotechnology · $515,277 market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2017
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 4, 2022 | Before the open | — | -23.01 | — |
| Feb 25, 2022 | Before the open | — | -4.55 | — |
| Dec 1, 2021 | Time not confirmed | — | -4.12 | — |
| Sep 1, 2021 | Time not confirmed | — | -14.90 | — |
| Jun 2, 2021 | Time not confirmed | — | -10.97 | — |
| Mar 3, 2021 | Time not confirmed | — | -12.27 | — |
| Dec 2, 2020 | Time not confirmed | — | 5.88 | — |
| Sep 2, 2020 | Time not confirmed | — | -63.53 | — |
| Jun 3, 2020 | Time not confirmed | — | -25.97 | — |
| Feb 26, 2020 | Time not confirmed | — | -211.26 | — |
| Nov 27, 2019 | Time not confirmed | — | -26.72 | — |
| Aug 28, 2019 | Time not confirmed | — | -55.16 | — |
| May 29, 2019 | Time not confirmed | — | -48.61 | — |
H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The…
| Time not confirmed |
| — |
| -54.97 |
| — |
| Nov 28, 2018 | Time not confirmed | — | -64.43 | — |
| Aug 29, 2018 | Time not confirmed | — | -57.83 | — |
| May 30, 2018 | Time not confirmed | — | -58.39 | — |
| Mar 30, 2018 | After the close | — | -76.31 | — |